Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: March 2026 (Report No. 2)
Date of Filing: March 9, 2026
This filing serves to furnish a press release regarding a clinical guideline update. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report containing a press release and does not include financial statements or quantitative financial data.
Material Changes
No material financial changes are reported in this filing. The primary update is non-financial, concerning a recommendation by the American Society of Breast Surgeons (ASBrS).
Guidance, Outlook, and Management Commentary
- Key Event: On March 9, 2026, the Company issued a press release titled "American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer."
- Significance: The ASBrS Resource Guide update now recommends cryoablation for low-risk breast cancer, which is relevant to the Company's core technology.
- Management Commentary: The filing incorporates the press release by reference but does not contain additional narrative commentary from management beyond the signature of the CEO, Eyal Shamir.
- Risks and Contingencies: No specific risks or contingencies are detailed in the body of this Form 6-K.
Important Facts for Investor Verification
- Verify the full text of the ASBrS Resource Guide update referenced in Exhibit 99.1 to understand the specific scope of the cryoablation recommendation.
- Confirm the potential commercial impact of this guideline update on Icecure Medical's product adoption rates.
- Review the Company's most recent Form 20-F or quarterly reports for actual financial performance data, as this filing contains none.